Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 4-6, 2008, Pages 629-636

  Yan, Dongmei ^a   Yang, Yingbao ^a   Uchida, Sinya ^b   Misaka, Shingen ^b   Luo, Jinghui ^a   Takeuchi, Kazuhiko ^a   Inui, Naoki ^a   Yamada, Shizuo ^b   Ohashi, Kyoichi ^c   Watanabe, Hiroshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

CYP3A; Drug interaction; Midazolam; Pharmacodynamics; Pharmacokinetics; Ursodeoxycholic acid

Indexed keywords

CYTOCHROME P450 3A; INTESTINE ENZYME; LIVER ENZYME; MIDAZOLAM MALEATE; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ANALYTICAL PARAMETERS; BODY POSTURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL; POSTURAL SWAY LENGTH; RANDOMIZED CONTROLLED TRIAL; SACCADIC EYE MOVEMENT; VISUAL ANALOG SCALE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTI-ANXIETY AGENTS; CHOLAGOGUES AND CHOLERETICS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; URSODEOXYCHOLIC ACID;

EID: 45849104647     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0217-z     Document Type: Conference Paper

References (40)

1. Amlot R, Walker R, Driver J, Spence C (2003) Multimodal visual-soma-to-sensory integration in saccade generation. Neuropsychologia 41:1-15
2. Becquemont L, Glaeser, H, Drescher, S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF (2006) Effects of ursodeoxycholic acid on p-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther 79:449-460
3. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
4. Bock HH, Lammert F (2002) Nuclear xeno-sensors as a receptors for cholestatic bile acid: the second line of defense. Hepatology 35:232-234
5. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4 beta-hydroxycholesterolin humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem 276:38685-38689
6. Bodin K, Lindbom U, Diczfalusy U (2005) Novel pathways of biocile acid metabolism involving CYP3A4. Biochim Biophys Acta 1687:84-93
7. Bond A, Lader M (1974) The use of analogue scale in rating subjective feelings. Br J Med Psychol 47:211-218
8. Burk O, Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn-Schmiedeberg's Arch Pharmacol 369:105-124
9. Dey A, Yadav S, Dhawan A, Seth PK, Parmar D (2006) Evidence for cytochrome P450 3A expression and catalytic activity in rat blood lymphocytes. Life Sci 79:1729-1735
10. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392
11. Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcová A, Hadasova E (2005) Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sci 78:239-244
12. Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A. Drug Metab Pharmacokinet 18:287-295
13. Emoto C, Murase S, Sawada Y, Iwasaki K (2005) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20:351-357
14. Floyd MD, Gervasini G, Masica AL, Mayo G, George ALJ, Bhat K, Kim RB, Wilkinson G (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606
15. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17
16. Kosuge K, Yang J, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K (2001) Effects fo CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos 29:1284-1289
17. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB (1999) In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 66:40-50
18. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28
19. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955
20. Macias RI, Jimenez S, Serrano MA, Monte MJ, Marin JJ (2006) Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci 79:1014-1019
21. Mc Donnell CG, Harte S, O'Driscoll J, O'Louahlin C, Van Pelt FD, Shorten GD (2003) The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 58:899-904
22. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen P (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305
23. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24
24. Paolini M, Pozzetti L, Montagnani M, Potenza G, Sabatini L, Antelli A, Cantelli-Forti G, Roda A (2002) Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CXP and preservation of BSEP activities. Hepatology 36:305-314
25. Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36:525-31
26. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229
27. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D, Guzelian PS (1993) Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocyte. Hepatology 18:1254-1262
28. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD (2001) Disrepted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276:39411-39418
29. Shimada T, Gillam EMJ, Sandhu P, Guo Z, Tukey RH, Guengerich FP (1994) Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays. Carcinogenesis 15:2523-2529
30. Strelevitz TJ, Foti RS, Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341
31. Theofilopoulos N, Szabadi E, Bradshaw CM (1984) Comparison of the effects of ranitidine and thioridazine on psychomotor functions in healthy volunteers. Br J Clin Pharmacol 18:135-144
32. Thomas AW, White KP, Drost DJ, Cook CM, Prato FS (2001) A comparison of rheumatoid arthritis and fibromyalagia patients and healthy controls exposed to a pulsed (200 micro T) magnetic field: effects on normal standing balance. Neurosci Lett 309:17-20
33. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502
34. Thummel KE, Kunze KL, Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Del Rev 27:99-127
35. Tsunoda SM, Velez RL, von-Moltke L, Gre-Lenbl DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471
36. Van SA, Kroon J, Schoemaker H, Pieterss P, Breimer D, Cohen A (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analogue lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 50:172-180
37. Wandel C, Böcker R, Böhrer H, Browne A, Rüghrimer E, Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesthe 73:658-661
38. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
39. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355
40. Zolner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38:717-727